Signal-enhanced MRI contrast agents for neurodegeneration

Información del proyecto

NeuroHyp

Identificador del acuerdo de subvención: 101100608

DOI

10.3030/101100608

Proyecto cerrado

Fecha de la firma de la CE 30 Septiembre 2022

Fecha de inicio 1 Octubre 2022

Fecha de finalización 31 Marzo 2024

Financiado con arreglo a

• European Research Council (ERC)

Coste total

Sin datos

Aportación de la UE

€ 150 000,00

Coordinado por

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany

Periodic Reporting for period 1 - NeuroHyp (Signal-enhanced MRI contrast agents for neurodegeneration)

Período documentado: 2022-10-01 hasta 2024-03-31

Resumen del contexto y de los objetivos generales del proyecto

The project was aimed at testing novel contrast agents approaches based on signal enhancements in magnetic resonance in the context of an early detection of neurodegeneration. Signal enhancement of hyperpolarization boosts normal magnetic resonance signals by over four orders of magnitude. This enables to use small molecules and body-own metabolites as potential contrast agents to directly monitor e.g. metabolic events.The idea was to pursue preclinical studies to follow onsets of the disease with new molecular imaging agents. This may be used in conjunction with potential therapies in order to assess whether a treatment for neurodegenerative diseases was successful and to diagnose them early.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The main aim was to investigate if a newly developed contrast agents approach could be used to probe neurodegenerative diseases and can be used for an early detection of such. With respect to the scientific part, we experienced difficulties obtaining groups with specific genotypes. This is overall considered a statistical outlier. We therefore did have large control groups but only insufficient group sizes with neurodegeneration. Overall a trend was observed that the contrast agent could serve as an identification for neurodegenerative diseases (p=0.06 when comparing wildtypes with groups having neurodegeneration as genotype). However, for a full validation further experiments are needed and we are aiming to attract further research funding.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Only trend were observed during the project with no statistical significance. These trends need to be followed up on in the future with further investigations.